Free Content Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis

Authors: Jansen1; Van Oene,2

Source: Alimentary Pharmacology & Therapeutics, Volume 13, Number 12, December 1999 , pp. 1611-1620(10)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: 

In the treatment of reflux oesophagitis, H2-receptor antagonists are still widely used in spite of the apparent higher efficacy of proton pump inhibitors. In an attempt to compensate for the lower efficacy, H2-receptor antagonists are now increasingly being used at a higher dose. Objective: 

To assess whether or not standard-dose lansoprazole (30 mg o.d.) is more effective than high-dose ranitidine (300 mg b.d.) in moderately severe reflux oesophagitis (grades II-III). Methods: 

Lansoprazole or ranitidine was given to 133 patients for 4-8 weeks in a double-blind, randomized, parallel group, multicentre trial. Results: 

The percentage of patients with endoscopically-verified healing was significantly higher on lansoprazole than on ranitidine both after 4 weeks (79% vs. 42%) and 8 weeks (91% vs. 66%), though smoking had a negative impact on oesophagitis healing with lansoprazole. Heartburn, retrosternal pain and belching improved significantly better with lansoprazole than with ranitidine, as did the patient-rated overall symptom severity. Relief of heartburn appeared somewhat faster with ranitidine, but was more pronounced with lansoprazole. The number of patients with adverse events was similar in both treatment groups. Conclusion: 

Standard-dose lansoprazole is better than high-dose ranitidine in moderately severe reflux oesophagitis.

Document Type: Research article

DOI: 10.1046/j.1365-2036.1999.00656.x

Affiliations: 1: Department of Gastroenterology, Academic Hospital Nijmegen St. Radboud, Nijmegen, the Netherlands, 2: Department of Clinical Research, Janssen-Cilag BV, Tilburg, the Netherlands

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on Synergy.

You may be required to register and activate access on Synergy before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A